GLP-1 weight-loss drug, whose full name is Glucagon-like peptide-1 receptor agonist. Initially, GLP-1 was a hormone secreted by the gastrointestinal tract mainly used for treating diabetes, but it has also been used to suppress appetite and control weight.
- 1979.809
- -7.494-0.38%
Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793
Analysts' Opinions Are Mixed on These Healthcare Stocks: KalVista Pharmaceuticals (KALV), Roche Holding AG (OtherRHHVF) and Pfizer (PFE)
Eli Lilly and Co Analyst Ratings
Eli Lilly & Co (LLY) Gets a Buy From Barclays
UBS Raises Price Target on Eli Lilly to $1,100 From $910, Maintains Buy Rating
Hold Rating on Pfizer: Caution Advised Amid Uncertainties Surrounding Danuglipron
Analysts Offer Insights on Healthcare Companies: Demant (OtherWILLF) and Pfizer (PFE)
Jefferies Sticks to Their Buy Rating for Pfizer (PFE)
Amgen Analyst Ratings
Berenberg Maintains Buy on Eli Lilly and Co, Raises Price Target to $1000
Analysts' Top Healthcare Picks: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Armata Pharmaceuticals (ARMP)
Morgan Stanley Adjusts Price Target on Amgen to $303 From $310
Berenberg Adjusts Price Target on Eli Lilly & Co. to $1,000 From $850, Maintains Buy Rating
Novo Nordisk (0QIU) Receives a Buy From J.P. Morgan
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN) and Pfizer (PFE)
Eli Lilly and Co Analyst Ratings
Pfizer Analyst Ratings
Barclays Remains a Buy on Eli Lilly & Co (LLY)
Eli Lilly and Co Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Natera (NTRA) and Argenx Se (ARGX)